BACKGROUND:Rifapentine administered 5 days per week has potent activity in mouse models of antituberculosis chemotherapy, but efficacy and safety data are limited in humans. We compared the antimicrobial activity and safety of rifapentine vs rifampin during the first 8 weeks of pulmonary tuberculosis treatment. METHODS: In total, 531 adults with sputum smear-positive pulmonary tuberculosis were randomized to rifapentine 10 mg/kg/dose or rifampin 10 mg/kg/dose, administered 5 days per week for 8 weeks (intensive phase), with isoniazid, pyrazinamide, and ethambutol. Coprimary outcomes were negative sputum culture on liquid and on solid media at completion of intensive phase. RESULTS: Negative cultures on solid media occurred in 145 of 174 participants (83.3%) in the rifampin group and 171 of 198 participants (86.4%) in the rifapentine group (difference, 3.0%; 95% confidence interval [CI]: -4.3, 10.5); negative cultures in liquid media occurred in 110 of 169 (65.1%) in the rifampin group and 133 of 196 (67.9%) in the rifapentine group (difference, 2.8%; 95% CI: -6.9, 12.4). Among 529 participants who received study therapy, 40 of 254 participants (15.7%) in the rifampin group and 40 of 275 participants (14.5%) in the rifapentine group prematurely discontinued treatment (P=.79). CONCLUSIONS: The rifapentine regimen was safe but not significantly more active than a standard rifampin regimen, by the surrogate endpoint of culture status at completion of intensive phase. Assessment of higher exposures to rifapentine for tuberculosis treatment is warranted. CLINICAL TRIALS REGISTRATION: NCT00694629.
RCT Entities:
BACKGROUND:Rifapentine administered 5 days per week has potent activity in mouse models of antituberculosis chemotherapy, but efficacy and safety data are limited in humans. We compared the antimicrobial activity and safety of rifapentine vs rifampin during the first 8 weeks of pulmonary tuberculosis treatment. METHODS: In total, 531 adults with sputum smear-positive pulmonary tuberculosis were randomized to rifapentine 10 mg/kg/dose or rifampin 10 mg/kg/dose, administered 5 days per week for 8 weeks (intensive phase), with isoniazid, pyrazinamide, and ethambutol. Coprimary outcomes were negative sputum culture on liquid and on solid media at completion of intensive phase. RESULTS: Negative cultures on solid media occurred in 145 of 174 participants (83.3%) in the rifampin group and 171 of 198 participants (86.4%) in the rifapentine group (difference, 3.0%; 95% confidence interval [CI]: -4.3, 10.5); negative cultures in liquid media occurred in 110 of 169 (65.1%) in the rifampin group and 133 of 196 (67.9%) in the rifapentine group (difference, 2.8%; 95% CI: -6.9, 12.4). Among 529 participants who received study therapy, 40 of 254 participants (15.7%) in the rifampin group and 40 of 275 participants (14.5%) in the rifapentine group prematurely discontinued treatment (P=.79). CONCLUSIONS: The rifapentine regimen was safe but not significantly more active than a standard rifampin regimen, by the surrogate endpoint of culture status at completion of intensive phase. Assessment of higher exposures to rifapentine for tuberculosis treatment is warranted. CLINICAL TRIALS REGISTRATION: NCT00694629.
Authors: Vikram Saini; Nicole C Ammerman; Yong Seok Chang; Rokeya Tasneen; Richard E Chaisson; Sanjay Jain; Eric Nuermberger; Jacques H Grosset Journal: Antimicrob Agents Chemother Date: 2019-05-24 Impact factor: 5.191
Authors: Gustavo E Velásquez; Meredith B Brooks; Julia M Coit; Henry Pertinez; Dante Vargas Vásquez; Epifanio Sánchez Garavito; Roger I Calderón; Judith Jiménez; Karen Tintaya; Charles A Peloquin; Elna Osso; Dylan B Tierney; Kwonjune J Seung; Leonid Lecca; Geraint R Davies; Carole D Mitnick Journal: Am J Respir Crit Care Med Date: 2018-09-01 Impact factor: 21.405
Authors: Susan E Dorman; Payam Nahid; Ekaterina V Kurbatova; Stefan V Goldberg; Lorna Bozeman; William J Burman; Kwok-Chiu Chang; Michael Chen; Mark Cotton; Kelly E Dooley; Melissa Engle; Pei-Jean Feng; Courtney V Fletcher; Phan Ha; Charles M Heilig; John L Johnson; Erica Lessem; Beverly Metchock; Jose M Miro; Nguyen Viet Nhung; April C Pettit; Patrick P J Phillips; Anthony T Podany; Anne E Purfield; Kathleen Robergeau; Wadzanai Samaneka; Nigel A Scott; Erin Sizemore; Andrew Vernon; Marc Weiner; Susan Swindells; Richard E Chaisson Journal: Contemp Clin Trials Date: 2020-01-22 Impact factor: 2.226
Authors: Kimberley N Chapman; Eric Pevzner; Joan M Mangan; Peter Breese; Dorcas Lamunu; Robin Shrestha-Kuwahara; Joseph G Nakibali; Stefan V Goldberg Journal: AJOB Empir Bioeth Date: 2015-02-19
Authors: Noton K Dutta; Abdullah Alsultan; Charles A Peloquin; Petros C Karakousis Journal: Antimicrob Agents Chemother Date: 2013-01-07 Impact factor: 5.191
Authors: Eric L Nuermberger; Ian M Rosenthal; Rokeya Tasneen; Charles A Peloquin; Khisimuzi E Mdluli; Petros C Karakousis; Jacques H Grosset Journal: Antimicrob Agents Chemother Date: 2013-02 Impact factor: 5.191
Authors: Alvaro A Ordonez; Hechuan Wang; Gesham Magombedze; Camilo A Ruiz-Bedoya; Shashikant Srivastava; Allen Chen; Elizabeth W Tucker; Michael E Urbanowski; Lisa Pieterse; E Fabian Cardozo; Martin A Lodge; Maunank R Shah; Daniel P Holt; William B Mathews; Robert F Dannals; Jogarao V S Gobburu; Charles A Peloquin; Steven P Rowe; Tawanda Gumbo; Vijay D Ivaturi; Sanjay K Jain Journal: Nat Med Date: 2020-02-17 Impact factor: 53.440
Authors: Susan E Dorman; Radojka M Savic; Stefan Goldberg; Jason E Stout; Neil Schluger; Grace Muzanyi; John L Johnson; Payam Nahid; Emily J Hecker; Charles M Heilig; Lorna Bozeman; Pei-Jean I Feng; Ruth N Moro; William MacKenzie; Kelly E Dooley; Eric L Nuermberger; Andrew Vernon; Marc Weiner Journal: Am J Respir Crit Care Med Date: 2015-02-01 Impact factor: 21.405